BlackThorn Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the lives of people with neurobehavioral disorders through the discovery and development of novel, targeted treatments. BlackThorn is building a robust pipeline of first- and best-in-class treatments, and is redefining the industry approach to drug discovery and development through its INFORM™ platform, which links brain physiology and its relationship to behavior. With its network of collaborations with leading academic investigators, BlackThorn is developing and deploying a set of technologies that will enable focused, rapid, resource-efficient translational studies for drug development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/21/16 | $40,000,000 | Series A |
Alexandria Real Estate Equities Altitude Life Science Ventures ARCH Venture Partners Johnson & Johnson Innovation Mercury Fund | undisclosed |
| 06/13/19 | $76,000,000 | Series B |
Alexandria Venture Investments Altitude Life Science Ventures ARCH Venture Partners Biomatics Capital GV Johnson & Johnson Innovation Mercury Fund Polaris Partners Premier Partners Scripps Research Vertex Ventures | undisclosed |
